Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
|Articles|August 15, 2014
- BioPharm International-08-15-2014
- Volume 2014 eBook
- Issue 2
Keys to Successful Method Transfer
Author(s)Cynthia A. Challener
Methods must be suitable at each development phase, robust, and effective on multiple platforms.
Advertisement
Methods must be suitable at each development phase, robust, and effective on multiple platforms.
from BioPharm International’s 2014 Analytical and Bioanalytical eBook.
Articles in this issue
about 12 years ago
The Challenge of Finding the Unknownabout 12 years ago
Testing the Quality, Safety, and Efficacy of Insulin Biosimilarsabout 12 years ago
Using the Purity Quotient Difference to Assess Protein Purificationabout 12 years ago
Standardizing Data ManagementAdvertisement
Related to this article
Advertisement
Advertisement
Trending on BioPharm International
1
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
2
FAQ: When Big Pharma Drops a Drug Candidate, Who Picks It Up?
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
5